This study aims to isolate endothelial progenitor cells (EPCs) from participants with type 2 diabetes (T2D) and cardiovascular complications and to comprehensively characterize EPC dysfunction. Specifically, the study will evaluate maladaptive angiocrine signaling, calcium signaling pathways, and the role of inflammation in EPC function and the progression of atherosclerosis during T2D development. A sub-study will assess EPC functionality by examining endothelial nitric oxide synthase (eNOS) expression and activity, as well as the effectiveness of in vitro eNOS gene enhancement.
T2D
Males and females
Older than 18 years of age
Willingness to participate in the study and provide written consent form
Unable to meet the inclusion criteria
Type I diabetes, MODY diabetes or other form of diabetes
Active infection, inflammation, cancer or acute illness of any kind (other than a cardiovascular complication of diabetes if applicable in the group they are assigned to).
Chronic inflammation (eg. auto-immune diseases) or infections (eg. HIV, chronic hepatitis).
Weill Cornell Medical College in Qatar
Lead sponsor
Hamad Medical Corporation
Collaborator